Table 1 Clinical data for patients with... | American Society of Hematology

Table 1

Clinical data for patients with CLL with known 17p status*

Characteristic	17pDEL (N = 64)	NORM/NORM (N = 40)	P, χ² test
No. of male/female	46/18	26/14	.131
Median age at diagnosis, y (range)	63 (37-89)	61 (37-76)	.095
Median time from diagnosis to sample collection, mo	75.10	81.29
ZAP-70 expression			.215
20% or less	21	17
More than 20%	43	23
IgVH status*			.035
Unmutated (≥ 98% homology)	36	18
Mutated (< 98% homology)	10	14
B2M expression*			.002
No more than 4 mg/L	27	29
More than 4 mg/L	26	6
Therapy began after collection
No	16	18	.587
Yes	14	16
If therapy received, median time since collection, mo	1.37	0.68
Treatment-refractory disease	18	0	< .001

Characteristic	17pDEL (N = 64)	NORM/NORM (N = 40)	P, χ² test
No. of male/female	46/18	26/14	.131
Median age at diagnosis, y (range)	63 (37-89)	61 (37-76)	.095
Median time from diagnosis to sample collection, mo	75.10	81.29
ZAP-70 expression			.215
20% or less	21	17
More than 20%	43	23
IgVH status*			.035
Unmutated (≥ 98% homology)	36	18
Mutated (< 98% homology)	10	14
B2M expression*			.002
No more than 4 mg/L	27	29
More than 4 mg/L	26	6
Therapy began after collection
No	16	18	.587
Yes	14	16
If therapy received, median time since collection, mo	1.37	0.68
Treatment-refractory disease	18	0	< .001

ZAP-70 indicates 70-kDa ζ-associated protein; IgVH, immunoglobulin heavy-chain variable-region gene; and B2M, β-2 microglobulin.

Status of IgVH and B2M was known for 78 and 88 patients, respectively.